Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

Enables expansion of ongoing vitiligo clinical study to U.S. investigational sitesTopline data anticipated Q4 2027

Edesa Biotech gains FDA clearance for EB06 vitiligo trial

FDA clearance allows Edesa to add U.S. sites to its Phase 2 EB06 study in up to 80 adults, with topline vitiligo data expected in late 2027.

FDA clears Edesa’s IND for Phase 2 vitiligo study - BioTuesdays

Edesa Biotech (NASDAQ: EDSA) has announced that the FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment to the U.S. According to Edesa, patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin […]